Back to top

Image: Bigstock

Top Ranked Income Stocks to Buy for September 11th

Read MoreHide Full Article

Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 11th:

Park National Corporation (PRK - Free Report) : This bank holding company has witnessed the Zacks Consensus Estimate for its current year earnings rising 2.1% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 3.49%, compared with the industry average of 1.81%. Its five-year average dividend yield is 4.14%.

Old Republic International Corporation (ORI - Free Report) : This insurance holding company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.9% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 3.44%, compared with the industry average of 1.92%. Its five-year average dividend yield is 4.26%.

Northwest Bancshares, Inc. (NWBI - Free Report) : This bank holding company has witnessed the Zacks Consensus Estimate for its current year earnings rising 2% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 3.71%, compared with the industry average of 1.75%. Its five-year average dividend yield is 4.03%.

MetLife, Inc. (MET - Free Report) : This global provider of insurance programs has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 3.67%, compared with the industry average of 1.92%. Its five-year average dividend yield is 2.95%.

MetLife, Inc. Dividend Yield (TTM)

MetLife, Inc. Dividend Yield (TTM)

MetLife, Inc. dividend-yield-ttm | MetLife, Inc. Quote

See the full list of top ranked stocks here

Find more top income stocks with some of our great premium screens.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>